Tempus AI (NASDAQ:TEM) Shares Down 7.8% - Should You Sell?

Shares of Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) fell 7.8% during trading on Tuesday . The stock traded as low as $82.62 and last traded at $82.47. 11,643,962 shares were traded during trading, a decline of 15% from the average session volume of 13,738,480 shares. The stock had previously closed at $89.44.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Guggenheim assumed coverage on shares of Tempus AI in a research note on Monday, December 9th. They issued a "buy" rating and a $74.00 price objective for the company. Stifel Nicolaus cut Tempus AI from a "buy" rating to a "hold" rating and raised their price objective for the company from $45.00 to $65.00 in a research note on Monday, November 11th. Needham & Company LLC reiterated a "buy" rating and issued a $56.00 price objective on shares of Tempus AI in a report on Tuesday, January 14th. TD Cowen restated a "buy" rating and set a $74.00 target price (up from $58.00) on shares of Tempus AI in a report on Wednesday, February 5th. Finally, Bank of America lifted their price target on Tempus AI from $52.00 to $54.00 and gave the stock a "neutral" rating in a research note on Friday, December 13th. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $58.55.

Tempus AI Stock Performance

The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. The company has a 50 day moving average price of $49.75 and a 200-day moving average price of $51.44.

Insider Activity at Tempus AI

In other Tempus AI news, CAO Ryan M. Bartolucci sold 13,770 shares of the company's stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $60.00, for a total transaction of $826,200.00. Following the transaction, the chief accounting officer now owns 57,237 shares in the company, valued at approximately $3,434,220. This represents a 19.39 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Eric P. Lefkofsky sold 187,655 shares of the firm's stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $37.54, for a total value of $7,044,568.70. Following the completion of the transaction, the chief executive officer now owns 9,557,283 shares of the company's stock, valued at approximately $358,780,403.82. The trade was a 1.93 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 2,583,467 shares of company stock worth $130,542,311 over the last quarter.

Institutional Trading of Tempus AI

Hedge funds have recently modified their holdings of the business. GF Fund Management CO. LTD. bought a new position in shares of Tempus AI in the 4th quarter worth about $108,000. Voloridge Investment Management LLC bought a new position in shares of Tempus AI during the fourth quarter valued at approximately $11,826,000. Two Sigma Advisers LP purchased a new position in shares of Tempus AI during the fourth quarter valued at approximately $625,000. ProShare Advisors LLC bought a new stake in shares of Tempus AI in the 4th quarter worth approximately $244,000. Finally, Lazard Asset Management LLC bought a new stake in shares of Tempus AI in the 4th quarter worth approximately $1,034,000. Institutional investors own 24.22% of the company's stock.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.